Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGTX Cognition Therapeutics, Inc

Closed Good Friday 04-02 16:00:00 EDT

0.8680

-0.0234

-2.63%

盘后0.8700

+0.0020+0.23%

19:56 EDT

High0.8832	Low0.8201	Vol1.05M
Open0.8600	D1 Closing0.8914	Amplitude7.08%
Mkt Cap77.56M	Tradable Cap71.64M	Total Shares89.35M
T/O890.44K	T/O Rate1.27%	Tradable Shares82.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGTX","market":"US","secType":"STK","nameCN":"Cognition Therapeutics, Inc","latestPrice":0.868,"timestamp":1775160000000,"preClose":0.8914,"halted":0,"volume":1048986,"hourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.868,"latestTime":"19:56 EDT","volume":41236,"amount":35057.2697,"timestamp":1775174178274,"change":0.002,"changeRate":0.002304,"amplitude":0.059447},"delay":0,"changeRate":-0.026250841373120906,"floatShares":82532000,"shares":89353773,"eps":-0.32277,"marketStatus":"Closed Good Friday","change":-0.0234,"latestTime":"04-02 16:00:00 EDT","open":0.86,"high":0.8832,"low":0.8201,"amount":890440.5775824001,"amplitude":0.070788,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.32277,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":0.8914,"preHourTrading":{"tag":"盘前","latestPrice":0.87,"preClose":0.8914,"latestTime":"09:25 EDT","volume":60276,"amount":50031.43920264,"timestamp":1775136300081,"change":-0.0214,"changeRate":-0.024007,"amplitude":0.090532},"postHourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.868,"latestTime":"19:56 EDT","volume":41236,"amount":35057.2697,"timestamp":1775174178274,"change":0.002,"changeRate":0.002304,"amplitude":0.059447},"volumeRatio":0.27634351173553384},"requestUrl":"/m/hq/s/CGTX/tweets","defaultTab":"tweets","newsList":[{"id":"2624530008","title":"Cognition Therapeutics announces availability of CEO shareholder letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530008?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:41","pubTimestamp":1774989684,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .Letter outlined plan to advance zervimesine  into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in Q2 2026.Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbhM7WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622580387","title":"Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622580387","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622580387?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:46","pubTimestamp":1774644372,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryCognition Therapeutics Inc CGTX.OQ reported a quarterly adjusted loss of 5 cents per share for the quarte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F22K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829802","title":"Cognition Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829802","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829802?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:11","pubTimestamp":1774613460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 08:11 ET (12:11 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622285338","title":"Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285338","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285338?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:35","pubTimestamp":1774607715,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics, with a price target of $3.00. Ram...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-buy-rating-backed-by-zervimesine-pivotal-path-and-risk‑adjusted-upside-across-neurodegenerative-indications-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-buy-rating-backed-by-zervimesine-pivotal-path-and-risk‑adjusted-upside-across-neurodegenerative-indications-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622285429","title":"Cognition Therapeutics 2025 net loss narrows as expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285429?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:39","pubTimestamp":1774525151,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics 2025 net loss narrows as expenses fallOverviewUS biopharmaceutical firm's 2025 net loss narrowed as operating expenses declinedCompany ended 2025 with $37 mln in cash, plus $35.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E0EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622285465","title":"Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285465","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285465?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:32","pubTimestamp":1774524779,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of $(0.17) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51477830/cognition-therapeutics-q4-eps-0-01-beats-0-05-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622928854","title":"Cognition Therapeutics Inc: Meeting With FDA Division of Psychiatry Expected by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622928854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622928854?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA5VWNZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854655","title":"Press Release: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854655","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854655?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"- Meeting with FDA Division of Psychiatry expected by mid-2026 -. \"Our progress in 2025 and early 2026 has culminated in a clinical development plan to advance zervimesine for the treatment of psychosis associated with DLB. This patient population has no approved options today and has demonstrated their support of zervimesine's advancement to registrational trials,\" said Lisa Ricciardi, Cognition's president and CEO. \"We received valuable feedback from regulators on both our DLB and Alzheimer's programs. Our 545-patient 'START' trial in early Alzheimer's disease has completed enrollment. Upon reviewing the results in 2027, we will determine how to advance zervimesine in Alzheimer's disease. With our near-term focus on DLB, our next steps are centered on a meeting with the FDA Division of Psychiatry to seek alignment on our registrational plan for zervimesine for the treatment of DLB psychosis.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","LU0240878834.USD","LU0345774631.USD","LU0345774391.USD","BK4007","LU0205193047.USD","LU0240877869.USD","CGTX","LU0348723411.USD","DLB","LU0205194284.USD","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTGO","BITF","EQ","IMDX","EPAC","CNTB","MKC","IKT","FUL","BIRD","BCAX","CMC","BHST","AIRO","DERM","AUTL","RNXT","GOVX","CCL","HYPD","EDAP","KOD","CNTX","ABOS","BAK","FEMY","AIRJ","KALV","JEF","DMAC","JILL","FDS","AGX","CGNT","HUMA","BNZI","CGTX","CDLR","JBS","IMNN","AURA","NKE","CHWY","DEFT","DOO","BYND","CTAS","CNTA","CELC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621062056","title":"Cognition Therapeutics Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062056","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062056?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:46","pubTimestamp":1774356367,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc  expected to post a loss of8cents a share - Earnings Preview Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to  show no change in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C1EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621477024","title":"Cognition Therapeutics to report Q4 and full-year 2025 financial results and host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2621477024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621477024?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265414,"startTime":"0","endTime":"0","summary":"Cognition will release financial results for the fourth quarter and full year ended December 31, 2025 on March 26, 2026, before the market opens.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL3MsKjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4588","SG9999014021.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","CGTX","LU2210149790.SGD","SG9999014013.SGD","BK4007","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620173429","title":"Cognition Therapeutics reports 86% slowing of NPI-12 decline with zervimesine in Phase 2 DLB study","url":"https://stock-news.laohu8.com/highlight/detail?id=2620173429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620173429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:31","pubTimestamp":1773747077,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics presented an analysis from its Phase 2 COG1201 SHIMMER study of zervimesine  in dementia with Lewy bodies at the AD/PD 2026 conference. The company reported that zervimesine was associated with an 86% slowing of decline on the NPI-12 measure versus placebo in the Phase 2 study. The analysis focused on treatment effects on behavioral and psychiatric symptoms commonly associated with dementia with Lewy bodies. Cognition said it plans to develop zervimesine for the treatment of psychosis in dementia with Lewy bodies following a Type C meeting with the FDA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8brVTf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","BK4007","IE00BN0W2T93.GBP","SG9999014013.SGD","CGTX","LU2210150020.SGD","BK4112","LU0314104364.USD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429768","title":"Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429768?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., March  17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257029/0/en/Cognition-Therapeutics-Presents-Evidence-of-Zervimesine-s-Impact-on-Neuropsychiatric-Symptoms-of-Dementia-with-Lewy-Bodies-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","CGTX","BK4023","LU0348723411.USD","BK4132","DLB","LU1169590202.USD","LU0240877869.USD","AD","LU0345774391.USD","LU0205194284.USD","LU0240878834.USD","BK4007","LU1169589451.USD","LU0345774631.USD","PD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619639084","title":"Cognition Therapeutics Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619639084","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619639084?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:48","pubTimestamp":1773665287,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc  expected to post a loss of8cents a share - Earnings Preview Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to  show no change in quarterly revenue when it reports  r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N40415J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616342095","title":"Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342095","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342095?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:35","pubTimestamp":1772624153,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. Ram Selvaraju has gi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-fda-aligned-late-stage-path-for-zervimesine-in-dlb-psychosis-and-alzheimers-supports-reiterated-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-fda-aligned-late-stage-path-for-zervimesine-in-dlb-psychosis-and-alzheimers-supports-reiterated-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","CGTX","DLB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616345283","title":"Cognition Therapeutics Advancing Zervimesine (Ct1812) for Dementia With Lewy Bodies (Dlb) Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2616345283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616345283?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:30","pubTimestamp":1772454648,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334605","title":"Cognition - to Meet FDA Division of Psychiatry to Discuss a Dlb Psychosis Program by Midyear 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616334605?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:30","pubTimestamp":1772454648,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0WB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616345513","title":"Cognition Therapeutics Plans Registrational Development Program for Zervimesine in DLB Psychosis, Including New Randomized Study and FDA Psychiatry Division Meeting by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616345513","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616345513?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:30","pubTimestamp":1772454633,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Plans Registrational Development Program for Zervimesine in DLB Psychosis, Including New Randomized Study and FDA Psychiatry Division Meeting by Mid-2026. Cognition Therapeutics said it plans to advance zervimesine  toward a registrational development path for treating psychosis in dementia with Lewy bodies. The company’s next DLB study is planned to evaluate neuropsychiatric and behavioral symptoms using established validated endpoints, randomizing participants to 100 mg oral zervimesine or placebo daily, followed by eligibility for an open-label extension. Cognition also plans to meet with the FDA’s Division of Psychiatry by midyear 2026 to discuss the proposed DLB psychosis program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLr2VYj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","BK4585","LU2210150020.SGD","BK4112","SG9999014005.SGD","BK4588","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","CGTX","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609585971","title":"BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609585971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609585971?lang=en_us&edition=fundamental","pubTime":"2026-02-06 02:48","pubTimestamp":1770317327,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF BanksharesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL6N3Z10QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTU","PTON","XOM","NVDG","BMY","SPWR","CFBK","FCFS","TPR","RIOT","CARR","ROK","FORM","SIRI","NVDX","APA","AVGX","ALGN","NFLX","VVOS","NEM","ELF","LRCX","AVGU","NVDU","CAH","CDE","NVII","CI","OSW","HL","CGTX","SYM","ADT","HUT","CVX","CMS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2609377438","title":"BRIEF-Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609377438","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609377438?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:33","pubTimestamp":1770294797,"startTime":"0","endTime":"0","summary":"BRIEF-Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy BodiesFeb 5 (Reuters) - Cognition Therapeutics Inc CGTX.O:COGNITION THERAPEUTICS EXTENDS EXP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z10QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogrx.com","stockEarnings":[{"period":"1week","weight":-0.1963},{"period":"1month","weight":-0.149},{"period":"3month","weight":-0.4095},{"period":"6month","weight":-0.44},{"period":"1year","weight":1.1022},{"period":"ytd","weight":-0.357}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.060065},{"month":2,"riseRate":0,"avgChangeRate":-0.189802},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073136},{"month":4,"riseRate":0.8,"avgChangeRate":0.022613},{"month":5,"riseRate":0.5,"avgChangeRate":-0.080419},{"month":6,"riseRate":0.25,"avgChangeRate":-0.038614},{"month":7,"riseRate":0.25,"avgChangeRate":0.074037},{"month":8,"riseRate":0.5,"avgChangeRate":0.719491},{"month":9,"riseRate":0,"avgChangeRate":-0.232471},{"month":10,"riseRate":0.5,"avgChangeRate":0.012004},{"month":11,"riseRate":0.2,"avgChangeRate":0.100902},{"month":12,"riseRate":0.4,"avgChangeRate":0.102692}],"exchange":"NASDAQ","name":"Cognition Therapeutics, Inc","nameEN":"Cognition Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cognition Therapeutics, Inc,CGTX,Cognition Therapeutics, Inc股票,Cognition Therapeutics, Inc股票老虎,Cognition Therapeutics, Inc股票老虎国际,Cognition Therapeutics, Inc行情,Cognition Therapeutics, Inc股票行情,Cognition Therapeutics, Inc股价,Cognition Therapeutics, Inc股市,Cognition Therapeutics, Inc股票价格,Cognition Therapeutics, Inc股票交易,Cognition Therapeutics, Inc股票购买,Cognition Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}